

**Sample Receipt Details:**

POD : \_\_\_\_\_ Temp : \_\_\_\_\_  
 Date & Time : \_\_\_\_\_ Sample Type : \_\_\_\_\_  
 CS Name & Sign : \_\_\_\_\_ Logistics Name & Sign : \_\_\_\_\_  
 Prenatal Sample  Yes  No Bill type  MOU  Retail  Research

## TEST REQUISITION FORM

Disease Segment\* \_\_\_\_\_  
 Each sample must be accompanied by this completed requisition. \* Fields are mandatory

**Test Details**

MGMT gene methylation analysis (Temozolomide Resistance)  
 FISH for 1p19q co-deletion, 1p3619q13  
 IDH1 and IDH2 Gene Analysis

Test Name\* : \_\_\_\_\_ Test Code\* : **MGM207 , MGM467 , MGM 1341**  
 Sample type:  Blood (in EDTA tube)  Blood (in Streck tube)  DNA, Specify Source: \_\_\_\_\_  Buccal swab  
 Amniotic Fluid  CVS  Cultured CV  Cultured amniocytes  
 Fetal Blood (PUBS)  Maternal blood for MCC (please send for prenatal studies)  Products of Conception (POC), specify tissue: \_\_\_\_\_  FFPE tissue Block (Block no. ....)  
 Fresh Frozen Tissue  Saliva  Other sample type (specify site) \_\_\_\_\_  DBS/FTA  
**N327/25**

Patient had a blood transfusion:  Yes  No Date of last transfusion: \_\_\_\_ / \_\_\_\_ / \_\_\_\_ (minimum 3 days of wait time is required for genetic testing)  
 Has he/she undergone allogenic bone marrow transplant:  Yes  No **One wax Block**

**Patient Details**

Name\* : **Mr. M.I.M. Ibrahim** D.O.B. **DD MM YY** Age\* : **60Y/M** Gender\* : **M / F**  
(In Capital Letters)  
 Address: \_\_\_\_\_  
 Phone: \_\_\_\_\_ E-mail I.D: \_\_\_\_\_

**Clinician Details**

Clinician's Name\* : **Prof. Jayantha Balawardana** Hospital Affiliation: **Aegle Omics Pvt Ltd**  
 Address: \_\_\_\_\_ Phone : \_\_\_\_\_  
 \_\_\_\_\_ Email id : \_\_\_\_\_  
 Date of sample collection\* : **25/4/2025 YY**

I understand that the current analysis is limited to variants which co-relate with disease phenotype/symptoms/terms as mentioned in the clinical details provided by me. Incidental findings which may or may not be actionable are not routinely reported. They can however be provided on request after informed consent from the patient/guardian. As disease phenotype may evolve over time, the appearance of new symptoms/signs may alter test results or their significance: MedGenome laboratories cannot be held responsible for this. A re-analysis or a re-test may be required due to the former; this will be performed (if deemed necessary) at an additional cost. I am authorised to order the above tests as I am the treating physician/consulting physician in this case. I confirm that the patient/guardian (in case of minors) has been provided complete information regarding the test, including its limitations in a language of their understanding.

**Dr. MAHENDRA PERERA**  
 MBBS (Cch), MD (Cch), Dip RT  
 Consultant in Clinical Oncology  
 & Radiotherapy

Medical Professional Signature\* \_\_\_\_\_ Date: \_\_\_\_\_ Place: \_\_\_\_\_  
 Clinical notes/diagnosis: \_\_\_\_\_  
 Disease affection status  Yes  NO Parental consanguinity present  Yes  NO Age of manifestation: \_\_\_\_\_  
 Affected Siblings  Yes  NO Details: \_\_\_\_\_

**GOVERNING LAW, JURISDICTION AND DISPUTE RESOLUTION**

These Terms and Conditions and this Test Requisition Form shall be governed by and construed in accordance with Indian law and the courts in Bangalore shall have exclusive injunctive jurisdiction. In the event of any dispute, controversy or claim whatsoever arising from these Terms and Conditions and/or this Test Requisition Form, the parties shall undertake to make every effort to reach an amicable settlement within fifteen (15) days upon reference of the dispute by any party through discussions among the concerned representatives of parties, failing which the dispute, controversy or claim shall be settled by Arbitration by a Sole Arbitrator appointed by the 'President-Arbitration Centre-Karnataka', Bangalore as per Indian Arbitration and Conciliation Act, 1996 as amended from time to time. The venue of arbitration shall be Bangalore and it shall be conducted in English language. The award passed by the Sole Arbitrator shall be final and binding upon the parties.

**NOTICE**

All notices, statements or other communication required or permitted to be given or made shall be in writing and in English language. Such notices will deliver by hand or sent by prepaid post with recorded delivery, or facsimile transmission addressed to the intended recipient at the address mentioned in this Test Requisition Form.

**INDEPENDENT PARTIES**

All parties effected hereunder are independent entities and neither of the parties are an agent, employee or joint venture of the other and they shall not represent themselves as such to any third parties.

**REFUND**

Refund of fees for any reason has to be claimed by the Patient or the guardians of the Patients within 90 days from the date of delivery of report.

**Patient/Guardian Authorization**

By my signature below I attest to the following:

I have read and I understand the information provided on this form.

**Patient Consent (sign here or on the consent document)**

I have read the Informed Consent document and I give permission to MedGenome to perform genetic testing as described. I also give permission for my specimen / genetic data to be used in (de-identified) studies at MedGenome to improve genetic testing for other patients.


By agreeing to this informed consent below, I am confirming that I understand the benefits, risks and limitations associated with genetic testing. Furthermore, I am affirming that I recognize the seriousness of conditions for which {I am/my child} being tested, and that disease descriptions, prognoses, and treatment options have been made available to me by {my/my child's} health care provider. Finally, if I have the legal authorization to provide this informed consent on behalf of another person, I am attesting that the sample provided belongs to that person.

Patient/Guardian Name Mr. M.I.M. Ibrahim

First Name \_\_\_\_\_ Middle Name \_\_\_\_\_ Last Name \_\_\_\_\_ Date of Birth: mm/dd/yyyy \_\_\_\_\_

Patient/Guardian Signature\* \_\_\_\_\_ Date: \_\_\_\_\_ Place: \_\_\_\_\_

Father Name \_\_\_\_\_ Mother Name \_\_\_\_\_

Signature\*  \_\_\_\_\_ Date and time \_\_\_\_\_ Signature\* \_\_\_\_\_ Date and time \_\_\_\_\_

Relationship with the proband \_\_\_\_\_

**Note :**

Signature of both parents is requested for prenatal testing.

For trio testing, each parent should provide separate informed consent for the sequencing of his or her sample.

10/05/25

Dr. Ibrahim

1 High grade glioma 2  
Brain

Dabw Kong son

News

IDH 1

IDH 2

1 p 19q Co-deletion

**PROF. JAYANTHA BALAWARDANE**  
MBBS, MD, FRCP(C), FRCR, FRCR (Gen), FSLCO  
Professor in Oncology  
Head of the Department of Oncology  
Faculty of Medicine  
University Hospital  
General Sri John Kotelawala Defence University

Rej

077 736 1457

21, Kirimandala Mawatha, Colombo 05, Sri Lanka.  
Tel : 4524400 Fax : 4527311 E-mail : info@asiri.lk

Consultant Histopathologist  
Punchihewa, MBBS, D Path, MD

Dr. Ramani Punchihewa  
MBBS, D.Path, MD (Histopathology)  
Consultant Pathologist

**Department of Histopathology**  
**The National Hospital of Sri Lanka**

Telephone: 011 269111 Ext. 2475

**Histopathology Report**

CONFIDENTIAL

Date Received : Friday, April 25, 2025

Pathology Report No. : N/327/2025

Name : M.M. Ibrahim

Age : 60 years Sex: Male

Ward : 81

BHT: 075685

Date of print: Wednesday, May 7, 2025

History : Presented with worsening upper limb and lower limb weakness.

Specimen : NNG Biopsy of Right cerebral lesion for histology.

Macroscopy : Multiple fragments together measuring 10x5x4mm. (one block).

Microscopy : The sections reveal largely necrotic tissue with scanty amount of viable tumour composed of atypical glial cells with markedly enlarged, pleomorphic nuclei and moderate eosinophilic cytoplasm. Few spindle areas are present. Microvascular proliferation or mitoses are not seen in the scanty viable tumour tissue.

immunohistochemistry:-

Neoplastic cells show cytoplasmic positivity for GFAP.

Conclusion : Brain, right cerebral, NNG Biopsy :-  
-High grade glioma NOS. (CNS WHO grade 4)

Comments : Need molecular analysis of IDH1, IDH2 mutation for further differentiation.

Registrar Dr.K.Amarawickrama  
Thursday, May 8, 2025

Dr. Ramani Punchihewa, MBBS, D Path, MD(Hist)  
Consultant Histopathologist

Dr. Ramani Punchihewa  
MBBS, D.Path, MD(Histopathology)  
Consultant Pathologist.  
National Hospital of Sri Lanka.

## RADIOLOGY AND IMAGING



Organization Accredited  
by Joint Commission International



**ASIRI**  
**HOSPITAL**  
LIVE MORE  
A Solstice Group Company

UHID : 130673104  
PATIENT'S NAME : MR M I MOHAMED IBRAHIM  
SCANNED REGION : MRI - BRAIN  
REQUESTED BY DR : DR GAMINI PATHIRANA  
REFERENCE NO : RC02208496  
DATE : 06-Apr-2025

PMR  
AGE : 59 Yrs  
SEX : MALE  
PLAIN : X  
ENHANCED :

### MRI BRAIN

Imaging Technique : Pre-contrast axial DWI, T1, T2 FLAIR; coronal T2 FSE and sagittal T1, MRA - Brain  
Comparison : None

### REPORT :

There is a heterogeneous intensity large lesion measuring 7.1 x 7.7cm in the right posterior temporal and occipital lobe. It has perilesional oedema. It is T1 hypointense and T2 hyperintense.

Few haemorrhages noted within it.

Similar 2.2 x 1.4cm lesion seen in the splenium of the corpus callosum.

Midline shift to the left side with compression over the right lateral ventricle.

Rest of the ventricular system appears normal in size. No hydrocephalus.

Normal sulci and gyri. Grey white demarcation is preserved.

Basal cisterns and other CSF containing spaces appear unremarkable.

No focal abnormality is detected in the region of the hypothalamus or pituitary gland.

No evidence of CP angle lesion is seen.

The posterior fossa is unremarkable.

### MRA Brain

Both intracranial internal carotid arteries appear normal in course, calibre and branching pattern. Both middle cerebral arteries and anterior cerebral arteries appear normal. The basilar and both posterior cerebral arteries appear normal in course, calibre and branching pattern. Normal anatomical variants are noted.

### IMPRESSION

Two focal lesions in the right side cerebral and splenium of the corpus callosum are suspicious of primary brain tumours.

Midline shift to the left side.

Suggest contrast study with MR spectroscopy.

  
DR. UDAYA WANIGASIRI  
CONSULTANT RADIOLOGIST

DR. UDAYA WANIGASIRI  
MBBS, FSLCR, EDiR, MD Radiology  
SLMC Reg. No. 15011  
CONSULTANT RADIOLOGIST  
NHSL

CreateBy : Lahiru  
Modified By : Lahiru

RC02208496

Print Date : 6-Apr-2025 4:13 pm Page 1 of 2

RADIOLOGY AND IMAGING



UHID : 130009530  
PATIENT'S NAME : MR M.I.M. IBRAHIM  
SCANNED REGION : MRI - BRAIN  
REQUESTED BY DR : PROF JAYANTHA BALAWARDANA  
REFERENCE NO : RC01366468  
DATE : 18-May-2025  
PMR : ASH0225107  
AGE : 60 Yrs  
SEX : MALE  
PLAIN :  
ENHANCED : X

**MRI BRAIN - (CONTRAST)**

*Comparison made to the previous study of April 2024.*

**FINDINGS:**

Irregular mass lesion again seen in the right temporo-occipital region extending to the parietal lobe with peripheral enhancement now measuring 7.7 x 3.7cm compared to 7.2 x 3.3cm in the previous study. It is extending along the splenium of the corpus callosum towards the left side which appear more prominent in the current study.

Multiple smaller peripherally enhancing lesions seen in the adjacent temporal and occipital lobes.

There is oedema of the adjacent brain parenchyma with mass effect upon the right lateral ventricle.

There is a shift of the midline towards the left of 15.7mm compared to 8mm in the previous study.

Basal cisterns are partially effaced.

Grey white differentiation is normal in rest of both cerebral hemispheres.

Pituitary gland is normal.

Cerebellum, brainstem, bilateral CP angles, 7th and 8th nerve complexes also are normal.

**IMPRESSION**

The lesion in the right temporo-occipital region extending to the parietal lobe has minimally enlarged in comparison to the previous study with multiple smaller lesions in the adjacent brain parenchyma.

There is extension along the splenium of the corpus callosum towards the left side which is more prominent in the current study.

The mass effect is more with a shift of the midline towards the left.

Basal cisterns are partially effaced.

DR(MRS) LAKMALIE PARANAHEWA

CONSULTANT RADIOLOGIST

CreateBy : 2206744  
Modified By : 2206744

RC01366468

Print Date : 18-May-2025 10:59 am Page 1 of 1

Asiri Surgical Hospital PLC, No 21, Kirimandala Mawatha, Colombo 05, Sri Lanka  
CT, MRI, Mammography, X-ray, Ultrasound and Deka Scan  
Gamma Camera Studies / Scintigraphy and PET CT

T: +94 11 452 4400  
T: +94 78 878 1472  
T: +94 77 132 3288

E: inquiries@asiri.lk  
E: subctmri@asiri.lk  
E: nuclearmedicine@asiri.lk